MedCallyLooking up the FDA label…
Looking up the FDA label…
Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. Pravastatin Sodium is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of MI, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident CHD. Reduce the risk of total mortality by reducing coronary death, MI, revascularization, stroke/TIA, and the progression of coronary atherosclerosis in patients with clinically evident CHD. Reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL C in patients with primary hypercholesterolemia and mixed dyslipidemia. Reduce elevated serum TG levels in patients with hypertriglyceridemia. Treat patients with primary dysbetalipoproteinemia who are not responding to diet. …
Muscle Pain Patients should be advised to report promptly unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever or if these muscle signs or symptoms persist after discontinuing Pravastatin Sodium. Liver Enzymes It is recommended that liver enzyme tests be performed before the initiation of Pravastatin Sodium, and thereafter when clinically indicated. All patients treated with Pravastatin Sodium should be advised to promptly report any symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice. Embryofetal Toxicity Advise females of reproductive potential of the risk to a fetus, to use effective contraception during treatment, and to inform their healthcare provider of a known or suspected pregnancy. Lactation Advise women not to breastfeed during treatment with Pravastatin Sodium. Manufactured by: Appco Pharma LLC Piscataway, NJ 08854 Manufactured for: Biocon Pharma Inc., 485 US Highway 1 S Suite B305, Iselin NJ 08830-3009 USA Revised: 10/2020
Pravastatin is generally well tolerated; adverse reactions have usually been mild and transient. In 4-month-long placebo-controlled trials, 1.7% of pravastatin-treated patients and 1.2% of placebo-treated patients were discontinued from treatment because of adverse experiences attributed to study drug therapy; this difference was not statistically significant. In short-term clinical trials, the most commonly reported adverse reactions (≥2% and > placebo) regardless of causality were: musculoskeletal pain, nausea/vo…
Having one of these?
A doctor will tell you whether it matters and what to do about it. Written answer, a week of free follow-ups.
Ask a doctor — $19.99Hypersensitivity to any component of this medication. Active liver disease or unexplained, persistent elevations of serum transaminases. Pregnancy Lactation 4.1 Hypersensitivity Hypersensitivity to any component of this medication. 4.2 Liver Active liver disease or unexplained, persistent elevations of serum transaminases. 4.3 Pregnancy Atherosclerosis is a chronic process and discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hyperchole…
Adults: the recommended starting dose is 40 mg once daily. Use 80 mg dose only for patients not reaching LDL-C goal with 40 mg. Significant renal impairment: the recommended starting dose is pravastatin 10 mg once daily. Children (ages 8 to 13 years, inclusive): the recommended starting dose is 20 mg once daily. Adolescents (ages 14 to 18 years): the recommended starting dose is 40 mg once daily. 2.1 General Dosing Information The patient should be placed on a standard cholesterol-lowering diet before receiving Pra…
For the concurrent therapy of either cyclosporine, fibrates, niacin (nicotinic acid), or erythromycin, the risk of myopathy increases. Concomitant lipid-lowering therapies: use with fibrates or lipid-modifying doses (≥1 g/day) of niacin increases the risk of adverse skeletal muscle effects. Caution should be used when prescribing with Pravastatin Sodium. Cyclosporine: combination increases exposure. Limit pravastatin to 20 mg once daily. Clarithromycin: combination increases exposure. Limit pravastatin to 40 mg onc…
Taking something else alongside it?
Interaction warnings are written per drug, not for your particular combination. A doctor can check yours.
Ask about my combinationWorks in a similar way — hmg coa reductase inhibitors
These are different medicines in the same family, not swaps for each other. Which one suits you is a prescribing decision.